Table 4 Cumulative incidence ratios of breakthrough COVID-19 and hospitalization with COVID-19 pneumonia or death comparing Veterans who received mRNA-1273 ×3 with those who received BNT–162b2, overall and by sub-group

From: Comparative mRNA booster effectiveness against death or hospitalization with COVID-19 pneumonia across at-risk US Veteran populations

 

Overall cohort (N = 1,703,189)

Average-risk populations (N = 110,485)

High-risk populations (N = 1,592,704)

Age ≥ 65 with no high-risk conditions (N = 215,177)

High-risk co-morbid conditionsa (not immune-compromised) (N = 1,188,470)

Immuno-compromising conditionsb (N = 189,047)

COVID-19 outcome by vaccination and booster

Cumulative incidence ratios (95% CI)c

Cumulative incidence ratios (95% CI)c

Cumulative incidence ratios (95% CI)c

Cumulative incidence ratios (95% CI)c

Cumulative incidence ratios (95% CI)c

Cumulative incidence ratios (95% CI)c

Breakthrough COVID-19 (N = 21,186)

  mRNA-1273 ×3

Ref.

Ref.

Ref.

Ref.

Ref.

Ref.

  BNT162b2 ×3

1.2 (1.2, 1.2)

1.1 (1.0, 1.3)

1.2 (1.2, 1.3)

1.1 (1.0, 1.2)

1.2 (1.2, 1.3)

1.2 (1.1, 1.3)

Death or hospitalization with COVID-19 pneumoniad (N = 1637)

  mRNA-1273 ×3

Ref.

Ref.

Ref.

Ref.

Ref.

Ref.

  BNT162b2 ×3

1.3 (1.2, 1.4)

1.7 (0.5, 5.1)

1.3 (1.2, 1.4)

1.6 (0.9, 3.0)

1.4 (1.2, 1.6)

1.2 (1.0, 1.4)

  1. aAs defined by the Center for Disease Control and Prevention, older adults, people with medical conditions who are not immunocompromised, and pregnant and recently pregnant people.
  2. bImmunocompromised was defined based on medications and history of cancer (see supplement for list of meds).
  3. cCI indicates “confidence interval”.
  4. dDeath from all causes within 30 days of breakthrough COVID-19 infection.
Back to article page